minimal residual disease testing Companies

Top Industry Leaders in the Minimal Residual Disease Testing Market

Minimal Residual Disease Testing Key Companies

Latest Minimal Residual Disease Testing Companies Update:

Adaptive Biotechnologies Launched clonoSEQ for assessing MRD in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA), expanding their product portfolio and competitive edge.

Guardant Health Received FDA approval for LUNAR-TRIDENT assay for MRD detection in triple-negative breast cancer, increasing their presence in the solid tumor MRD market.

Natera Collaborated with AstraZeneca to develop and commercialize MRD tests for non-small cell lung cancer (NSCLC), leveraging their expertise in liquid biopsy technologies.

Exact Sciences Corporation Announced plans to acquire Astex Pharmaceuticals, gaining access to their MRD technology for colorectal cancer, strengthening their dominant position in this segment.

List of Minimal Residual Disease Testing Key companies in the market

Adaptive Biotechnologies (US)

Sysmex Inostics, Inc. (US)

Arup Laboratories Inc. (US)

ArcherDX, Inc. (US)

Asuragen Inc. (US)

Bio-Rad Laboratories, Inc. (US)

Guardant Health (US)

QIAGEN N.V. (Germany)

FOUNDATION MEDICINE, INC. (US)

GRAIL, Inc. (US)

Minimal Residual Disease Testing Companies

Minimal Residual Disease (MRD) testing is a technique used in oncology to detect and monitor small amounts of cancer cells that may remain in a patient's body after treatment. It helps assess the effectiveness of treatment and predict the likelihood of disease recurrence.

Top Industry Leaders in the Minimal Residual Disease Testing Market